劉俊人
教授
 
個人學經歷
 
<<學歷>>
台大醫學士(1992.6)
台大臨床醫學研究所博士 (2003.6)

<<經歷>>
財團法人恩主公醫院內科部主治醫師 (1997.7-1999.6)
台大醫學院內科臨床助理教授(2003.9)

<<現職>>
台大醫院內科部主治醫師 (1999.7-迄今)
台大醫學院臨床醫學研究所副教授(2007.8-迄今)
 
研究專長
 

內科,消化內科,肝臟學,分子生物學,轉譯醫學

實驗室可提供學習之實驗技術
PCR, Real time PCR, Transfection, Sequencing, Mutagenesis, Southern blot.


 
五年內著作
 
2008.1.1~迄今
1. Chou YC, Yu MW, Wu CF, Yang SY, Lin CL, Liu CJ, Shih WL, Chen PJ, Liaw YF, Chen CJ. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut 2008;57:91-97.
2. Wang CC, Hsu CS, Liu CJ, Kao JH. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol 2008;23:779-782.
3. Wu CF, Yu MW, Lin CL, Liu CJ, Shih WL, Tsai KS, Chen CJ. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis 2008;29:106-112.
4. Hsu CS, Liu CJ, Liu CH, Wang CC, Chen CL, Lai MY, Chen PJ, Kao JH, Chen DS. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 2008;28:271-277.
5. Tan A, Yeh SH, Liu CJ, Cheung C, Chen PJ. Viral hepatocarcinogenesis: From infection to cancer. (Review) Liver Int 2008;28:175-188.
6. Liu CJ, Kao JH. Core promoter mutations of hepatitis B virus and hepatocellular carcinoma: The story beyond A1762T/G1764A mutations. (Editorial) J Gastroenterol Hepatol 2008;23:347-350.
7. Shih YH, Yeh SH, Chen PJ, Chou WP, Liu CJ, Wang HY, Lu SF, Chen DS. Hepatitis B virus quantification and detection of YMDD mutants in a single reaction by real-time PCR and annealing curve analysis: Development and application. Antivir Ther 2008;13:469-480.
8. Hsu CS, Liu CJ, Liu CH, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH. Metabolic profiles in patients with chronic hepatitis C: a case–control study. Hepatol Int 2008;2:250-257.
9. Liu CH, Liang CC, Lin JW, Chen SI, Tsai HB, Chang CS, Hung PH, Kao JH, Liu CJ, Lai MY, Chen JH, Chen PJ, Kao JH, Chen DS. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 2008;57:525-30.
10. Liu CJ, Kao JH. Genetic variability of hepatitis B virus and response to antiviral therapy. (Review) Antivir Ther 2008;13:613-624.
11. Su TH, Liu CJ, Chen PJ, Chen DS, Kao JH. Acute fatty liver of pregnancy with concurrent acute hepatitis B virus infection. (Case report) Am J Gastroenterol 2008;103:2663-2665.
12. Liu CH, Hsu SJ, Liang CC, Tsai FC, Lin JW, Liu CJ, Yang PM, Lai MY, Chen PJ, Chen JH, Kao JH, Chen DS. Esophageal Varices: Noninvasive Diagnosis with Duplex Doppler US in Patients with Compensated Cirrhosis. Radiology 2008 248:132-139.
13. Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, Kao JH, Chen DS. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients. Liver Int 2008;28:1034-1041.
14. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: A follow-up study in Taiwan. Gastroenterology 2008;135:111-121.
15. Yu MW, Shih WL, Lin CL, Liu CJ, Jian JW, Tsai KS, Chen CJ. Body-mass index and progression of hepatitis B: A population-based cohort study in men. J Clin Oncol 2008;26:5576-5582. Oct 27 [Epub ahead of print]
16. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, Hsu CS, Tseng TC, Wang CC, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH. Peginterferon alfa-2a plus ribavirin for treatment-naïve Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008;47:1260-1269 (SCI)
17. Tsai YH, Kuang WF, Lu TY, Kao JH, Lai MY, Liu CJ, Chen PJ, Hwang LH. The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism. J Hepatol 2008;49:899-907.
18. Tseng PH, Liu CJ, Kao JH, Shun CT, Chen PJ, Chen DS. Disease progression in a patient with nonalcoholic steatohepatitis. J Formos Med Assoc 2008;107:816-821.
19. Liu CJ,* Jeng YM, Chen CL, Cheng HR, Chen PJ, Chen TC, Liu CH, Lai MY, Chen DS, Kao JH*. Hepatitis B virus basal core promoter mutation and DNA load correlate with expression of hepatitis B core antigen in chronic hepatitis B patients. J Infect Dis 2009;199:742-749. Jan 26 [Epub ahead of print] (*corresponding author) (NSC96-2628-B-002-076-MY3) (SCI)
20. Liu CJ, Huang YJ, Chen HL, Lin HT, Lin HL, Kuo ML, Huang JL, Chen DS, Chen PJ, Wu HL. Characterization of woodchuck interleukin 8 in woodchucks with chronic hepatitis B and hepatocellular carcinoma. Genes Immun 2009;10:27-36 (SCI)
21. Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Lee CC, Yu MC, Hu RH, Peng CY, Lai KL, Chang SC, Chen PJ. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and dose-finding. J Hepatol 2009;50:958-968. Epub 2009 Feb 15 (SCI)
22. Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, Liao LY, Chen CL, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Liu CH, Su WW, Lin CL, Jeng YM, Chen PJ, Chen DS. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis C and B viruses. Gastroenterology 2009;136:496-504 (online available, Oct. 25, 2008) (SCI)
23. Liu CJ, Chen PJ, Lai MY, Liu CH, Chen CL, Kao JH, Chen DS. High serum adiponectin correlates with advanced liver diseases in patients with chronic hepatitis B. Hepatol Int 2009;3:364-370.
24. Liu CJ, Chen PJ, Chen DS. Dual chronic hepatitis B virus and hepatitis C virus infection. (Review) Hepatol Int 2009;3:517-525.
25. Liu CJ, Chen PJ. Pharmacogenomics of chronic hepatitis C. (Research Highlights) Pharmacogenomics 2009;10:1039-1042.
26. Hsu CS, Liu CH, Liu CJ, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Antivir Ther 2009;14:45-54.
27. Tseng TC, Liu CJ, Hsieh SC, Chen PJ, Lai MY, Chen DS, Kao JH. Reactivation of hepatitis B virus in an inactive hepatitis B carrier with glucocorticoid pulse therapy. Dig Liver Dis 2009;41:322-323.
28. Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, Chen DS, Kao JH. Association of hepatitis B viral factors with response to lamivudine therapy in chronic hepatitis B patients with serum ALT over 5 times upper limit of normal. Antivir Ther 2009;14:203-210.
29. Huang YW, Hu CY, Chen CL, Liao YT, Liu CJ, Lai MY, Chen PJ, Yang SS, Hu JT, Chen DS, Kao JH. Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis activity in Taiwanese male hepatitis B carriers. J Med Virol 2009;81:588-593.
30. Liu CH, Liang CC, Liu CJ, Tsai HB, Hung PH, Hsu SJ, Chen SI, Lin JW, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH. Pegylated interferon alpha-2a plus ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. Gut 2009;58:314-316.
31. Hsu CS, Liu CH, Liu CJ, Wang CC, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. Am J Gastroenterol 2009;104:598-604. Epub 2009 Feb 10
32. Shih WL, Yu MW, Chen PJ, Wu TW, Lin CL, Liu CJ, Lin SM, Tai DI, Lee SD, Liaw YF. Evidence for association with hepatocellular carcinoma at the PAPSS1 locus on chromosome 4q25 in a family-based study. Eur J Hum Genet 2009; 17(10):1250-1269. Apr 1. [Epub ahead of print]
33. Chainuvati S, Cheng J, Hou JL, Hsu CW, Jia JD, Komolmit P, Kwon SY, Lee CH, Li H, Li Y, Liu CJ, Neo BL, Peng CY, Tanwandee T, Wongcharatrawee S, Wu JC, Yu ML, Zhang XX. Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand. Hepatol Int 2009 Jun 24. [Epub ahead of print]
34. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS, and Taiwan Hepatoma Study Group. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: A twenty-year follow-up study. J Natl Cancer I 2009;101:1348-1355.
35. Hsieh TH, Tseng TC, Liu CJ, Lai MY, Chen PJ, Hsieh HL, Chen DS, Kao JH. Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. Antivir Ther 2009;14:1157-1163.
36. Sung FY, Jung CM, Wu CF, Lin CL, Liu CJ, Liaw YF, Tsai KS, Yu MW. Hepatitis B virus core variants modify natural course of viral infection and hepatocellular carcinoma progression. Gastroenterology 2009;137(5):1687-97. [Epub ahead of print]
37. Huang YW, Liao YT, Chen W, Chen CL, Hu JT, Liu CJ, Lai MY, Chen PJ, Chen DS, Yang SS, Kao JH. Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan. Genes Immun 2010;11:87-93. [Epub ahead of print]
38. Yu ML, Lee CM, Chuang WL, Lu SN, Dai CY, Huang JF, Lin ZY, Hu TH, Chen CH, Hung CH, Wang JH, Chen CL, Kao JH, Lai MY, Liu CH, Su TH, Wu SS, Liao LY, Kuo HT, Chao YC, Tung SY, Yang SS, Chen PJ, Liu CJ, Chen DS. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J Infect Dis 2010:202(1):86-92. (corresponding author)
39. Chang LC, Chung CS, Liu CJ, Kao JH. Metabolic syndrome on top of chronic hepatitis B: the more, the worse? Gut 2010;59:276-277.
40. Huang YW, Chayama K, Tsuge M, Takahashi S, Hatakeyama T, Abe H, Hu JT, Liu CJ, Lai MY, Chen DS, Yang SS, Kao JH. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B. Antivir Ther 2010;15:177-184.
41. Liu CH, Liang CC, Liu CJ, Hsu SJ, Lin JW, Chen SI, Hung PH, Tsai HB, Lai MY, Chen PJ, Chen JH, Chen DS, Kao JH. The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C. Kidney Int 2010;78:103-109. [Epub ahead of print]
42. Hsu CS, Liu CH, Liu CJ, Hsu SJ, Chen CL, Hwang JJ, Lai MY, Chen PJ, Chen DS, Kao JH. Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection. J Gastroenterol Hepatol 2010;25:970-977.
43. Liu CH, Liang CC, Liu CJ, Lin JW, Chen SI, Hung PH, Tsai HB, Lai MY, Chen PJ, Chen DS, Kao JH. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C. Clin Infect Dis 2010;51(5):541-549.
44. Su TH, Chen PJ, Chen TC, Cheng HR, Li L, Lin KS, Kao JH, Chen DS, Liu CJ. The clinical significance of occult hepatitis B transfusion in Taiwan – a Look-back study. Transfusion Medicine 2010 Aug 18. [Epub ahead of print] (corresponding author)
45. Huang HH, Shih WL, Li YH, Wu CF, Chen PJ, Lin CL, Liu CJ, Liaw YF, Lin SM, Lee SD, and Yu MW. Hepatitis B viremia: its heritability and association with common genetic variation in the interferon {gamma} signaling pathway. Gut 2010 Jan;60(1):99-107. Epub 2010 Oct 27.
46. Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, Liu CJ, Chen PJ, You SL, Wang LY, Chen CJ. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: Long-term predictors from a community-based cohort study. J Clin Oncol 2010 Oct 20;28(30):4587-4593. Epub 2010 Sep 20.
47. Lee MH, Yang HI, Jen CL, Yeh SH, Liu CJ, You SL, Sun CA, Wang LY, Chen WJ, Chen CJ. Community and personal risk factors for HCV infection: A survey of 23,820 residents in Taiwan in 1991-1992. Gut 2010 Nov 10. [Epub ahead of print]
48. Lee MH, Yang HI, Wang CH, Jen CL, Yeh SH, Liu CJ, You SL, Chen WJ, Chen CJ. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 2010 Dec;41(12):2894-2900. Epub 2010 Oct 21.
49. Hsu CS, Wang CC, Wang PC, Lin HH, Tseng TC, Chen CH, Su WC, Liu CJ, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH. Increased incidence of gastroesophageal reflux disease in patients with chronic hepatitis B virus infection. Hepatol Int 2010;4:585-93.
50. Su TH, Hsu CS, Chen CL, Liu CH, Huang YW, Tseng TC, Liu CJ, Chen PJ, Lai MY, Chen DS, Kao JH. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir Ther 2010;15(8):1133-1139.
51. Hsu CS, Hsu SJ, Chen HC, Tseng TC, Liu CH, Niu WF, Jeng J, Liu CJ, Lai MY, Chen PJ, Kao JH, Chen DS. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Proc Natl Acad Sci U S A 2011;108:3719-3724. Feb 14. [Epub ahead of print]
52. Liu CJ, Cheng HR, Chen CL, Chen TC, Tseng TC, Wang ZL, Chen PJ, Liu CH, Chen DS, Kao JH. Effects of hepatitis B virus precore and basal core promoter mutations on expression of viral antigens: Genotype B versus C. J Viral Hepat 2011 Oct;18(10):e482-e490. (joint corresponding author)
53. Liu CH, Liang CC, Huang KW, Liu CJ, Chen SI, Lin JW, Hung PH, Tsai HB, Lai MY, Chen PJ, Chen JH, Chen DS, Kao JH. Transient Elastography to Assess Hepatic Fibrosis in Hemodialysis Chronic Hepatitis C Patients. Clin J Am Soc Nephrol 2011 Mar 10. [Epub ahead of print]
54. Chao LT, Wu CF, Sung FY, Lin CL, Liu CJ, Huang CJ, Tsai KS, Yu MW. Insulin, glucose, and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. Carcinogenesis 2011;32:876-881.
55. Hsu SJ, Hsu CS, Liu CH, Liu CJ, Chen CL, Chen PJ, Chen DS, Kao JH. HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection. Antivir Ther 2011;16:227-235.
56. Liu CJ, Chen PJ, Chen DS, Kao JH. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: Natural history, pathogenesis and management. Hepatol Int (review) (accepted)
57. Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, Chen DS, Kao JH. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011;141:517-525.
58. Mah YH, Hsu CS, Liu CH, Liu CJ, Lai MY, Chen PJ, Chen DS, Kao JH. Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan. Hepatol Int 2011 Feb 6. [Epub ahead of print]
59. Yeh ML, Hung CH, Huang JF, Liu CJ, Lee CM, Dai CY, Wang JH, Lin ZY, Lu SN, Hu TH, Yu ML, Kao JH, Chuang WL, Chen PJ, Chen DS. Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. PLoS One 2011;6(6):e20752. Epub 2011 Jun 13. (joint corresponding author)
60. Liang CC, Liu CH, Lin YL, Liu CJ, Chiang BL, Kao JH. Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy. J Med Virol 2011;83:1212-1220.
61. Lin CL, Tseng TC, Su TH, Liu CJ, Chen PJ, Lai MY, Chen DS, Kao JH. Host genetic variants and hepatitis B virological features in HBeAg-negative hepatitis B carriers with long-term biochemical remission. Hepatol Int 2012;6:598-605.
62. Pan CJ, Wu HL, Kuo SF, Kao JH, Tseng TC, Liu CH, Chen PJ, Liu CJ, Chen DS. Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B. Hepatol Int 2012;6:591-597. (corresponding author)
63. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo Stephanie, Liu CH, Chen PJ, Chen DS, Kao JH. Determinants of spontaneous surface antigen loss in HBeAg-negative patients with a low viral load. Hepatology 2012;55:68-76.
64. Tseng TC, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, Liu CH, Kuo SF, Pan CJ, Yang SS, Su CW, Chen PJ, Chen DS, Kao JH. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy. Antivir Ther 2011;16:629-37.
65. Tseng TC, Liu CJ, Chen CL, Wang CC, Su TH, Kuo SF, Chen PJ, Chen DS, Kao JH. Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverter. J Infect Dis 2012;205(1):54-63
66. Sheng WH, Hung CC, Chang SY, Liu CJ, Chen MY, Hsieh SM, Kao JH, Chen PJ, Chang SC. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy. Clin Infect Dis 2011 Dec 7. [Epub ahead of print]
67. Hsu CS, Liu CH, Wang CC, Tseng TC, Liu CJ, Chen CL, Chen PJ, Chen DS, Kao JH. Impact of hepatitis B virus infection on metabolic profiles and modifying factors. J Viral Hepat 2012;19(2):e48-57.
68. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012;142:1140-1149.
69. Shih WL, Chang HC, Liaw YF, Lin SM, Lee SD, Chen PJ, Liu CJ, Lin CL, Yu MW. Influences of tobacco and alcohol use on hepatocellular carcinoma survival. Int J Cancer 2012 Feb 23. doi: 10.1002/ijc.27508. [Epub ahead of print]
70. Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, Su TH, Hsu SJ, Lin JW, Chen JH, Chen PJ, Chen DS, Kao JH. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy. Antivir Ther 2011 Dec 20. doi: 10.3851/IMP2026. [Epub ahead of print]
71. Chen BF, Liu CJ, Jow GM, Chen PJ, Chen DS, Kao JH. Fine Mapping of Hepatitis B Virus pre-S Deletion and its Association with Hepatocellular Carcinoma. J Med Virol 2012 Jun 7. doi: 10.1111/j.1478-3231.2012.02826.x. [Epub ahead of print]
72. Liu CJ. Prevalence and risk factors for NAFLD in Asian people who are not obese. J Gastroenterol Hepatol 2012;27:1555-1160.
73. Yuan Q, Song LW, Liu CJ, Li Z, Liu PG, Huang CH, Yan Y, Ge SX, Wang YB, Peng CY, Zhang J, Kao JH, Chen DS, Chen PJ, Xia NS. Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. Gut 2013 Jan;62(1):182-4.
74. Liu CC, Wang YH, Chuang EY, Tsai MH, Chuang YH, Lin CL, Liu CJ, Hsiao BY, Lin SM, Liu LY, Yu MW. Identification of a liver cirrhosis signature in plasma for predicting hepatocellular carcinoma risk in a population-based cohort of hepatitis B carriers. Mol Carcinog 2012 Aug 21. doi: 10.1002/mc.21952. [Epub ahead of print]
75. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Hsu CA, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. Serum hepatitis B surface antigen levels help predict disease progression in patients with low HBV loads. Hepatology 2012 Sep 3. doi: 10.1002/hep.26041. [Epub ahead of print]
76. Yang HC, Chen CL, Shen YC, Peng CY, Liu CJ, Tseng TC, Su TH, Chuang WL, Yu ML, Dai CY, Liu CH, Chen PJ, Chen DS, Kao JH. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced HBeAg seroconversion. Hepatology 2012 Oct 30. doi: 10.1002/hep.26121. [Epub ahead of print]
77. Yu ML, Lee CM, Chen CL, Chuang WL, Lu SN, Liu CH, Wu SS, Liao LY, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Su WW, Lin CL, Yang HC, Chen PJ, Chen DS, Liu CJ, Taiwan Liver-Net Consortium. Sustained HCV clearance and increased HBsAg seroclearance in patients with dual chronic hepatitis C and B during post-treatment follow-up. Hepatology 2013 Jan 15. doi: 10.1002/hep.26266. (corresponding author)
78. Tseng TC, Liu CJ, Su TH, Yang HC, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation. J Infect Dis 2012;206:1521-1531.
79. Hsu CS, Hsu SJ, Liu WL, Liu CH, Chen CL, Liu CJ, Chen PJ, Chen DS, Kao JH. IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients. Antivir Ther 2013 Jan 7. doi: 10.3851/IMP2502. [Epub ahead of print]
80. Cheng HR, Liu CJ, Tseng TC, Su TH, Yang HI, Chen CJ, Kao JH. Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. PLOS ONE 2013;8:e53008.
 
BACK